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Introduction 
As pharmaceutical care continues to advance in the area of oncology, scientists 
have turned to nanoparticle delivery systems to improve upon existing anticancer 
agents. Exact definitions vary, but one commonly used definition from the National 
Nanotechnology Initiative defines nanotechnology as “science, engineering, and 
technology” on the order of 1 to 100 nanometers in any dimension1. The last two 
decades have witnessed enormous growth in the development of nanoparticle 
anticancer agents. In 1995, the FDA approved pegylated liposomal doxorubicin (PLD, 
Doxil ®) for the treatment of platinum-refractory ovarian cancer. Since that time, there 
has been extensive research into the use of liposomal agents for the treatment of 
various malignancies. The hope has been, and continues to be, that these agents can be 
used to target cytotoxic chemotherapy to malignant cells while minimizing exposure to 
healthy cells. Unfortunately, only two other nanoparticle agent, Abraxane® and 
Marqibo®, have come to market in the 20 years since the FDA approved Doxil ®. Other 
agents that have been studied as liposomal formulations but are not currently FDA 
approved include belotecan, irinotecan, lurtotecan, cisplatin, oxaliplatin, paclitaxel, and 
vinorelbine2.  
Nanoparticles, and liposomes in particular, are a favored method of drug 
delivery because they provide the ability to control the timing and location of a drug’s 
release3. An additional benefit of liposomal agents is reduced clearance compared to 
small molecule agents, providing more sustained drug concentrations and less frequent 
dosing4. It has been observed for some liposomal agents that concentrations in tumor 
tissue are 10 to 50 times that observed in circulation5. This finding is attributed to the 
enhanced permeation and retention (EPR) effect. Tumors secrete growth factors like 
VEGF that promote angiogenesis and help sustain the rapid growth of malignant cells. 
These new blood vessels are irregular and dilated with wide fenestrations, the epithelial 
cells are poorly aligned, and many vessels lack an underlying basement membrane or 
smooth muscle layer6. The extravasation of liposomes out of circulation is assisted by an 
imbalance between vasodilators (e.g. nitric oxide, bradykinin, prostaglandins) and 
vasoconstrictors (angiotensin II) in tumor tissue. In addition, tumor tissue has slow 
venous return and poor lymphatic drainage, leading to prolonged retention of 
liposomes and accumulation of the drug in tumor7.   
Small molecule drugs are not subject to the EPR effect and are rapidly cleared by 
the liver or kidney. Liposomes, due to their relatively larger size, are clearly by the 
immune cells of the mononuclear phagocyte system (MPS). The MPS comprises the 
circulating blood monocytes as well as resident tissue macrophages 8. The exact 
interaction between the MPS and liposomes is still not completely understood, as it 
involves a complex bidirectional interplay: the MPS cells in the body determine 
biodistribution and clearance of the liposome, and the antineoplastic agent 
encapsulated within the liposome can have a cytotoxic effect on the MPS9-12. Because 
liposomes are cleared from circulation by the MPS, they primarily accumulate in tissues 
with dense populations of these cells, notably the liver and spleen13.  
While liposomes and other nanoparticle agents have the advantages discussed 
above, they have not been more widely developed as commercial agents due to issues 
of pharmacokinetic (PK) and pharmacodynamics (PD) variability. Multiple studies have 
compared liposomal agents to their small molecule equivalent and confirmed that 
liposomes have significantly greater PK and PD variability14-17. The exact causes are still 
unclear, but there does appear to be a correlation between PK/PD variability and 
patient specific factors such as age, body composition, and clearance rate of the 
drug2,17.  
This PK/PD variability may help explain why some cancers respond to liposomal 
agents while other do not. PLD provides an excellent case study here. The FDA approved 
Doxil ® on the basis of a Phase 3 study showing a survival benefit compared to standard 
of care in platinum refractory ovarian cancer18. However, these benefits have not 
extended to other gynecologic cancers. A Phase 2 study designed to evaluate the 
antitumor activity in patients with persistent or recurrent endometrial carcinoma found 
limited activity and subsequent studies have not provided sufficient rationale to pursue 
this research further19.  
The expansion of liposomal anticancer agents to improve on current standard of 
care would be greatly simplified by a relatively rapid, affordable, and accurate marker to 
explain PK/PD variability and predict efficacy in specific patient populations. One 
potential candidate is the F4/80 marker for tumor associated macrophages (TAMs). 
TAMs are specific MPS cells that migrate to and exert their function within the tumor 
tissue. They are mediators of inflammation and are associated with poor prognosis20. 
TAMs regulate tumor growth, angiogenesis, invasion and metastasis through the release 
of cytokines, chemokines, enzymes, and growth factors21. Zamboni et al illustrated that 
the number of MPS cells associated with different tumor cell types correlated with 
distribution of a liposomal anticancer agent to tumor tissue, release of the agent within 
the tumor tissue, and tumor response to the agent22.  
The F4/80 marker is highly specific for MPS cells and survives tissue fixation and 
embedding, allowing the opportunity to visualize and quantify MPS cells in tissue 
samples8. The exact processing and staining methodology has been previously 
described23. MPS cells stain at varying levels of intensity, which can be quantified using 
the H Score calculation of Budwit-Novotny24. Cells are scored as stain: not present (0), 
weak but detectable (1+), distinct (2+), or strong (3+). 
Figure 1: Comparison of a melanoma (A375) and ovarian (SKOV-3) cancer cell line in 
terms of number of MPS cells, distribution of a liposomal cancer agent in an 
encapsulated (S-CKD602) and released (CKD-602) form, and tumor response.   















Figure 2: F4/80 staining in tumor tissue, illustrating how the various grades of staining 













































The following formula is then used to obtain an overall H Score, ranging from 0 to 400, 
for a tissue region or an entire tissue. 
 
𝐻 − 𝑠𝑐𝑜𝑟𝑒 =
(#𝑜𝑓𝑐𝑒𝑙𝑙𝑠𝑔𝑟𝑎𝑑𝑒 3) × 4 + (#𝑜𝑓𝑐𝑒𝑙𝑙𝑠𝑔𝑟𝑎𝑑𝑒 2) × 3 + (#𝑜𝑓𝑐𝑒𝑙𝑙𝑠𝑔𝑟𝑎𝑑𝑒 1) × 2
𝑡𝑜𝑡𝑎𝑙𝑛𝑢𝑚𝑏𝑒𝑟𝑜𝑓𝑐𝑒𝑙𝑙𝑠
×  100 
 
The goal of this honors project was to compare the pharmacokinetics and efficacy of 
PLD to small molecule doxorubicin in two xenograft mouse models, one endometrial 
(i.e. HEC1A) and one ovarian (i.e. SKOV-3), with differing TAM densities as measured by 
H Score analysis. PLD concentrations were measured separately for drug still within the 
liposomal carrier (i.e. encapsulated) and drug released from the liposomal carrier (i.e. 
released). It is important to note that encapsulated drug is pharmacologically inactive 
and possesses the PK properties of the carrier molecule, while released drug is active 




HEC1A and SKOV3 cells were obtained from the American Type Culture Collection 
(Rockville, MD) and expanded in culture by the Tissue Culture Facility at the University 
of North Carolina.  
 
Female CB17 SCID mice aged 8 to 12 weeks were purchased from Taconic Labs (Albany, 
NY) and were allowed to acclimate for 1 week at the UNC Lineberger Cancer Center 
prior to initiation of the study. The mice in the endometrial arm were injected with 
1,000,000 HEC1A xenograft cells in 25 uL volume into the uterine horn. The mice in the 
ovarian arm were injected with 200,000 SKOV3 xenograft cells in 5 uL volume into the 
ovarian bursa.  
 
Animal weights were obtained daily for 2 weeks, then biweekly for the remainder of the 
study. Tumor dimensions were measured by palpation biweekly for the duration of the 
study. Animals were sacrificed if tumors measured 2.0 cm in any direction or the animal 
lost 20% from maximum body weight achieved.  
 
PLD was purchased from FormuMax Scientific (Palo Alto, CA) and nonliposomal 
doxorubicin (NL-doxo) was purchased from Sigma Aldrich (St. Louis, MO). Dosing details 
for each phase of the study are provided in Table 1. In the PK portion of the study, drug 
was injected IV x 1 via a tail vein. In the efficacy portion of the study, drug was injected 
IV via a tail vein weekly for up to 6 doses or until the animal met criteria for harvest.  
Table 1: Dosing of PLD and NL-doxorubicin by study phase 




PK D5W 1.2 mg/mL NS 1.2 mg/mL 
Efficacy 
6 mg/kg 
D5W 1.2 mg/mL NS 1.2 mg/mL 
Efficacy 
3 mg/kg 
D5W 0.6 mg/mL NS 0.6 mg/mL 
 
In the PK and initial efficacy studies, mice were treated with PLD and NL-doxorubicin at 
6 mg/kg. Mice in the initial efficacy study did not tolerate multiple doses, so a follow up 
efficacy study was conducted comparing PLD and NL-doxorubicin at 3 mg/kg. In addition 
to the PLD and NL-doxorubicin arms for both mice bearing HEC1A and SKOV3 
xenografts, the efficacy studies included a “control” arm consisting of tumor bearing 
mice who received no treatment.  
 
PK samples were obtained prior to drug injection and at 5 min, 30 min, 1 hr, 3 hr, 6 hr, 
24 hr, 48 hr, 72 hr, and 96 hr post injection. Blood samples were placed on ice and 
processed the same day using a solid phase separation method described previously to 
isolate encapsulated and released drug fractions25. Tissues were snap frozen after 
collection and stored at -80°C until further processing. They were then homogenized 
with pH 7.4 PBS buffer at a 1:3 ratio of tissue:PBS and drug in tissue was isolated and 
measured using protein precipitation. Released doxorubicin in plasma, encapsulated 
PLD in plasma, and sum total doxorubicin in tissues were all measured using a high 
performance liquid chromatography assay25. Areas under the curve (AUCs) for overall 
drug exposure were calculated using Phoenix Version 6.2 (Pharsight Corp) with a linear 




PLD concentrations as measured in plasma, liver, and spleen were not significantly 
different between the mice bearing HEC1A and SKOV3 xenografts. AUC analysis showed 
that SKOV3 PLD exposures were 70%, 86%, 102%, and 143% of the HEC1A exposures for 
released drug in plasma, encapsulated drug in plasma, sum total drug in liver, and sum 
total drug in spleen, respectively. This compared to an SKOV3 PLD AUC in tumor tissue 
that was 263% of HEC1A AUC. PK data for plasma and tumor are plotted with respect to 
time in Figure 3 and Figure 4. At 3 hours, concentrations in SKOV3 tumor tissue 
averaged 11.2 times that in HEC1A tumor tissue. This differential gradually narrowed 
over time, but was still observed as far out as the 48 hour time point.  
Figure 3: Concentration vs. Time in plasma from 0 to 96 hours after administration of 
PLD at 6 mg/kg x 1 dose in female SCID mice bearing SKOV3 and HEC1A xenografts. 


















Figure 4: Concentration vs. Time in tumor from 0 to 96 hours after administration of 
PLD at 6 mg/kg x 1 dose in female SCID mice bearing SKOV3 and HEC1A xenografts. 







































































Similar trends were observed in the mice treated with NL-doxorubicin; however, the 
ratio of drug measured in tumor relative to plasma was not as great. SKOV3 NL-
doxorubicin exposures were 47% of HEC1A exposures for plasma and 116% for tumor. 
NL-doxorubicin accumulation in tumor, then, was 2.4 fold greater in SKOV3 than in 
HEC1A, while PLD accumulation in tumor was 3.8 fold greater in SKOV3 than in HEC1A.  
 
In the initial efficacy study at 6 mg/kg, median survival for HEC1A PLD vs. NL-doxorubicin 
vs. control was 13 days, 9 days and 27 days. Median survival for SKOV3 PLD vs. NL-
doxorubicin vs. control was 11 days, 9 days and 37 days. While PLD mice did survive, on 
average, longer than NL-doxorubicin mice, the control mice outperformed both 
treatments regardless of whether the mice were in the ovarian or endometrial group. In 
both the PLD and NL-doxorubicin groups, around ½ of the mice were harvested between 
the 1st and 2nd dose of treatment. By the time mice were scheduled to received their 3rd 
dose of treatment, less than 10% of mice remained in any of the treatment groups. On 
the basis of this limited data, it was not possible to properly compare survival between 
groups. The results of the initial efficacy study are presented in Figure 5.  
 
Figure 5: Survival data in mice carrying either SKOV3 ovarian or HEC1A endometrial 
xenografts who received pegylated liposomal doxorubicin (PLD) at 6 mg/kg, 






Figure 6: Survival data in mice carrying either SKOV3 ovarian or HEC1A endometrial 
xenografts who received pegylated liposomal doxorubicin (PLD) at 3 mg/kg, 




Accordingly, a follow up efficacy study was conducted at 3 mg/kg. These results are 
presented in Figure 6. In this study, median survival for HEC1A PLD vs. NL-doxorubicin 
vs. control was 14 days, 13 days and 13 days. Median survival for SKOV3 PLD vs. NL-
doxorubicin vs. control was 27 days, 23 days and 20 days. With the limited number of 
mice in each group, the potential trend toward improved survival in the SKOV3 mice 




Our findings in this study present more than one paradox. The pharmacokinetic data 
suggests a link between MPS function, as measured by the H score, and drug 
distribution to xenograft tumor tissue. Mice carrying representative ovarian (SKOV3) 
and endometrial (HEC1A) xenografts were given a single dose of PLD or NL-doxorubicin 
at 6 mg/kg. Mice tolerated this treatment well up to 96 hours, and data up to this point 
suggests minimal differences in plasma drug concentrations when comparing the two 
xenografts either based on released or encapsulated drug. However, the mice with 
ovarian xenografts, which had more MPS cells as measured by H Score analysis, 
accumulated more PLD in tumor tissue, suggesting that the increased number of TAMs 
migrating to the tumor in SKOV3 mice was helping to deliver the liposomal agent. This 
same benefit was not seen with NL-doxorubicin. 
 
However, this pharmacokinetic link did not translate to an efficacy advantage at either 
the initial 6 mg/kg or the subsequent repeat study at 3 mg/kg. Tumor bearing control 
mice who received no treatment outperformed both treatment groups for both types of 
xenografts at 6 mg/kg weekly. Moreover, it was noted that the vast majority of mice did 
not tolerate more than 2 doses of drug, whether liposomal or small molecule, 
suggesting that acute anthracycline toxicity is playing more of a role here than the 
cancer progression. The mouse facility noted prior issues with anthracycline toxicity in 
SCID mice on projects for other researchers; however, this had not previously been 
observed on Zamboni lab projects as we use other mouse models for these types of 
studies.  
 
The lower dose of 3 mg/kg also produced disappointing efficacy results. At this dose, 
SKOV3 mice had improved survival relative to HEC1A mice no matter the treatment arm. 
Median survival was consistent with the anticipated trend: PLD > NL-doxorubicin > 
control. However, this trend was not statistically significant. One interesting trend to 
note when comparing the 6 mg/kg data to the 3 mg/kg data is the fact that survival 
times for the HEC1A mice remained the same while survival times for the SKOV3 mice 
improved notably with the dose reduction. One possible explanation is that the survival 
benefit of PLD is still being obscured to some degree by acute anthracycline toxicity. 
Less than 1/3 of SKOV3 mice tolerated all 6 doses of PLD, and no HEC1A mice made it 
this far. The data for NL-doxorubicin is similar. 
 
This study emphasizes several limitations associated with the use of orthotopic 
xenograft mouse models. While orthotopic models are considered more physiologically 
accurate than flank models, these models are generally not considered as 
physiologically accurate as genetically engineered models (GEMMs). Several authors 
have noted that orthotopic xenografts are not sufficient to fully replicate the complex 
and heterogeneous tumor environment26-28. Additionally, SCID mice are not considered 
ideal surrogates because they are immunocompromised and have issues with proper 
DNA repair, resulting in unacceptably high rates of chemotherapy toxicity29. These 
results are consistent with our own. Nevertheless, xenograft mouse models are 
considered a rapid, inexpensive, and versatile method to model the development and 
progression of cancer in humans.  
 
One potential step moving forward is to perform one additional efficacy analysis in mice 
treated at 1 mg/kg. This dose should be sufficiently low enough that toxicity should not 
confound the results, allowing any potential survival benefit from PLD to become more 
clear over the 6 week treatment period.  
 
In summary, this study illustrates a link between the MPS and the distribution of PLD in 
orthotopic xenograft mouse models. The pharmacokinetic advantage of PLD is 
associated with tumor cell lines that have higher MPS population and is most likely a 
function of MPS uptake and delivery of liposomal anticancer agents preferentially to the 
tumor tissue. Unfortunately, whether this pharmacokinetic advantage translates into a 
benefit in terms of efficacy is still unknown. Researchers employing SCID mice for 
efficacy studies should be especially cautious in dosing these animals with 
anthracyclines, as they are particularly prone to toxicity.  
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